DADavid Joseph Askenazi

David Joseph Askenazi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Joseph Askenazi has a total of 444 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Weight changes and variability in the first week of life: associations with mortality in extremely preterm newborns

    by Serena Vigezzi, Elad Resnick, Enrico Vidal, Namasivayam Ambalavanan, Colm P. Travers, David J. Askenazi

    In extremely preterm newborns (ELGANs, < 28 weeks' gestational age [GA]), early weight trajectories reflect fluid balance, yet thresholds for early risk stratification are lacking. We aimed to evaluate whether percentage weight change (ΔW%) from birth weight (BW) and week-1 weight variability were independently associated with death by postnatal day 7 and to identify clinically relevant thresholds. We performed a retrospective single-center secondary analysis of the Golden Week Program (University of Alabama at Birmingham NICU, 2014-2021). Newborns < 28 weeks' GA with BW ≥ 400 g and receiving active treatment were included; exclusion criteria were death ≤ 48 h, major congenital anomalies, or incomplete weight data. Multivariable logistic regression was performed, adjusted for GA, 5-min Apgar score, and BW z-score; optimal cutoffs were derived using the Youden Index. Among 805 neonates, 55 (6.8%) died by day 7. Non-survivors had higher day-3 ΔW% than survivors (median - 5.3% vs. - 10.7%; p < 0.007). Day-3 ΔW% was independently associated with mortality (aOR 1.05; 95% CI 1.02-1.08), with an optimal cutoff of - 6.4% (sensitivity 57%, specificity 72%). Among variability metrics, total fluctuation (mean absolute day-to-day change in ΔW%) showed the best discrimination (aOR 1.45; 95% CI 1.29-1.65; AUC 0.84), with an optimal cutoff of 5.3% (sensitivity 76%, specificity 74%). ELGANs who do not lose 5-7% of BW by postnatal day 3 or exhibit an average day-to-day weight fluctuation > 5% of BW are at increased risk of early mortality. These weight-derived metrics may support early risk stratification but require prospective validation.

  • Open Access

    Reducing NICU ventilator days by preventing fluid overload with the CAN-U-P-LOTS standardized bundle

    by David J. Askenazi, Lindsey Gordon, Russell Griffin, Monica Collins, Allison Black, Namasivayam Ambalavanan, Tennille Webb, Meggie Mathis, Kara Short, Alyssa Umberger, et al.

    Background: Fluid overload in critically ill neonates and infants is associated with higher ventilation days, prolonged length of stay, and mortality. Methods: This quality improvement study enrolled infants admitted to Children’s of Alabama NICU (excluding those with tracheostomies, severe congenital kidney or heart disease, DNR status, or severe genetic conditions). We compared 7 months of pre-intervention data (211 neonates) with 7 months of post-implementation data (218 neonates). Bundle implementation for at least 5 days occurred for sepsis, spontaneous intestinal perforation, necrotizing enterocolitis, acute kidney injury, positive fluid balance >10%, hypotension, and major surgeries. The primary hypothesis was that the unit-wide ventilator-free days would increase after bundle implementation. Results: We found special cause variation with an increase in the percentage of ventilator-free and oxygen-free days coinciding with bundle introduction. The ventilator-free days were higher in the post-era compared to the pre-era (5592/8335 (67%) vs. (3732/6619) (56%); p < 0.001). Oxygen-free days and NICU length of stay showed similar findings. Conclusions: Implementation of a fluid overload prevention bundle was associated with increased ventilator-free days, oxygen-free days, and shortened NICU duration. Additional studies are needed to better understand these associations and externally validate our hypothesis in other populations. Impact: Fluid overload leads to poor clinical outcomes, including the need for ventilatory support. Prolonged ventilation has a deleterious effect on the lungs due to barotrauma and leads to complications (i.e., pneumonia), longer length of stay, and increased costs. After consensus from a multi-disciplinary team, we implemented a strategy using the CAN-U-P-LOTS bundle designed to prevent fluid overload in critically ill infants. We showed an increase in the number of ventilator-free days, oxygen-free days, and shorter length of stay. Studies are needed to validate our single-center study.


  • Open Access

    Postnatal Steroid Exposure in Extremely Low Gestational Age Newborns and Kidney Function at 24 Months Corrected Age

    by Meredith P. Schuh, Russel Griffin, Cara Slagle, David Selewski, Danielle E. Soranno, Megan J. Turner, Jennifer Varner, David Askenazi, Shina Menon, Katja M. Gist

    Key Points: Overall, steroid exposure was not associated with GFR at follow-up. Hydrocortisone duration of 1–7 days had 2.8 times increased odds of reduced GFR at 24-month corrected age. Dexamethasone given at ≤25 weeks postmenstrual age had 9.4 times increased odds of reduced GFR compared with those given dexamethasone at ≥29 weeks. Background: Preterm birth is associated with low nephron endowment, with an increased risk of CKD later in life. Almost all pregnant women at risk for preterm delivery are given antenatal corticosteroids to accelerate lung maturity in preterm neonates. Similar to antenatal steroids, postnatal corticosteroids are also given to improve lung function, but the effect on kidney function is unknown. The objective of this study was to determine if duration and timing of postnatal corticosteroids in preterm infants influences kidney function at 24-month corrected age. Methods: A secondary analysis of the Preterm Erythropoietin Neuroprotection Trial (neonates 2 at the 24-month corrected gestational age time point). Outcomes were adjusted for perinatal/neonatal exposures, and neonatal outcomes were compared. Results: Of 838 surviving infants, 397 (47%) were exposed to any postnatal steroid. Dexamethasone was the most common exposure (n=238, median start date at day of life 27, median duration of 8 days), followed by hydrocortisone (n=232, median start day of life 13, median duration 17 days). In total, 348 infants were evaluated at the 22–26-month follow-up, 61 of whom had reduced GFR. Hydrocortisone duration of 1–7 days had 2.8 (95% confidence interval, 1.06 to 7.62) times increased odds of reduced GFR at 24-month corrected age. Although overall steroid exposure was not associated with GFR at follow-up, initiation of dexamethasone at ≤25 weeks postmenstrual age was associated with 9.39 (95% confidence interval, 1.61 to 54.71) increased odds of reduced GFR compared with those given dexamethasone at ≥29 weeks. Conclusions: Although observational, this study supports an association between postnatal steroid timing, duration, and reduced GFR. Further studies are warranted to better understand this association to protect long-term kidney health.


  • Open Access

    The Landscape of Pediatric Acute Care Nephrology Programs

    by Keri Drake, Shina Menon, Kara Short, Katie Plomaritas, Brendan Crawford, Kyle Merrill, Alyssa Riley, Weiwen Vivian Shih, David Askenazi, David Selewski, et al.

    An abstract is unavailable. This article is available as a PDF only.


  • Vascular Access for Renal Replacement Therapy in Neonates and Infants: A Single Center Experience

    by Samantha M. Koenig, Wendelyn M. Oslock, Kara Short, Jessica Potts, David Askenazi, Chinwendu Onwubiko, Robert T. Russell, Vincent E. Mortellaro


  • Long-Term Kidney Outcomes after Pediatric Acute Kidney Injury

    by Cal H. Robinson, Nivethika Jeyakumar, Bin Luo, David Askenazi, Akash Deep, Amit X. Garg, Stuart Goldstein, Jason H. Greenberg, Cherry Mammen, Danielle M. Nash, et al.

    Key Points: Among 4173 children with AKI, 18% had major adverse kidney events (death, kidney failure, or CKD) during a median 10-year follow-up. AKI survivors were at 2–4 times higher risk of major adverse kidney events, hypertension, and subsequent AKI versus matched hospitalized comparators. This justifies improved surveillance after pediatric AKI to detect CKD and hypertension early and improve long-term kidney health. Background: AKI is common in hospitalized children. Pediatric AKI receiving acute KRT is associated with long-term CKD, hypertension, and death. We aim to determine the outcomes after AKI in children who did not receive acute KRT because these remain uncertain. Methods: Retrospective cohort study of all hospitalized children (0–18 years) surviving AKI without acute KRT between 1996 and 2020 in Ontario, Canada, identified by validated diagnostic codes in provincial administrative health databases. Children with prior KRT, CKD, or AKI were excluded. Cases were matched with up to four hospitalized comparators without AKI by age, neonatal status, sex, intensive care unit admission, cardiac surgery, malignancy, hypertension, hospitalization era, and a propensity score for AKI. Patients were followed until death, provincial emigration, or censoring in March 2021. The primary outcome was long-term major adverse kidney events (a composite of all-cause mortality, long-term KRT, or incident CKD). Results: We matched 4173 pediatric AKI survivors with 16,337 hospitalized comparators. Baseline covariates were well-balanced following propensity score matching. During a median 9.7-year follow-up, 18% of AKI survivors developed long-term major adverse kidney event versus 5% of hospitalized comparators (hazard ratio [HR], 4.0; 95% confidence interval [CI], 3.6 to 4.4). AKI survivors had higher rates of long-term KRT (2% versus <1%; HR, 11.7; 95% CI, 7.5 to 18.4), incident CKD (16% versus 2%; HR, 7.9; 95% CI, 6.9 to 9.1), incident hypertension (17% versus 8%; HR, 2.3; 95% CI, 2.1 to 2.6), and AKI during subsequent hospitalization (6% versus 2%; HR, 3.7; 95% CI, 3.1 to 4.5), but no difference in all-cause mortality (3% versus 3%; HR, 0.9; 95% CI, 0.7 to 1.1). Conclusions: Children surviving AKI without acute KRT were at higher long-term risk of CKD, long-term KRT, hypertension, and subsequent AKI versus hospitalized comparators.


  • Open Access

    KRT Designed for Infants: A Game Changer

    by Sukanya Govindan, Matthew C. Gillen, Kimberly J. Reidy, Arwa Nada, David J. Askenazi, Rupesh Raina

    An abstract is unavailable. This article is available as a PDF only.


  • Neonatal Kidney Dysfunction

    by Isabella Guzzo, Stefano Picca, David Askenazi


  • Use of extracorporeal therapies to treat life-threatening intoxications

    by Kyle Deville, Nathan Charlton, David Askenazi

    Toxic ingestions are a significant cause of pediatric morbidity and mortality, with some requiring extracorporeal removal for therapy. Given the emergent and life-threatening nature of such scenarios, it is paramount that clinicians caring for intoxicated children be familiar with the subject. This review summarizes the following: (a) the properties of a substance which lend it amenable to removal; (b) the current extracorporeal treatment modalities available for such removal (of which hemodialysis is typically the ideal choice); (c) an introduction and framework to use a quick reference guide from the Extrip organization, which has a website available to guide clinicians’ rapid decisions; and (d) new membranes/approaches that may optimize clearance of certain intoxications.